Loading

Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/breastcancer.3.016

NTRK fusions: A novel diagnostic and therapeutic methodology for cancer

  • 1College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA
  • 2West Cancer Center and Research Institute, Memphis, TN, USA
+ Affiliations - Affiliations

Corresponding Author

 Rishika Singh, rsingh15@uthsc.edu;

Nupur Singh, nsingh8@uthsc.edu

Received Date: January 20, 2023

Accepted Date: January 30, 2023

Abstract

This commentary discusses the case from the publication “Metastatic Triple Negative Breast Cancer with NTRK Gene Fusion on Tissue but not on ctDNA Molecular Profile.” This paper stresses the importance of molecular profiling to find characteristic mutations such as NTRK gene fusions which increase therapeutic options including tyrosine receptor kinase inhibitors such as Larotrectinib and entrectinib. The current profiling techniques are also discussed with both advantages and limitations discussed. Genomic testing in relation to current pharmaceutical therapies will shape the future of cancer diagnosis and treatment.

Keywords

NTRK fusion, Molecular profiling, Secretory breast cancer, Triple negative breast cancer, Larotrectinib, Tyrosine receptor kinase inhibitors

Author Information X